Bristol Myers Squibb (CELG-RI) Receivables (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Receivables of $10.7 billion for Q2 2026, down 18.73% year-over-year from $13.1 billion in Q2 2025, and down 1.2% quarter-over-quarter from $10.8 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Receivables (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Receivables for 18 consecutive years, with $10.7 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables fell 18.73% year-over-year to $10.7 billion; the TTM figure through Jun 2026 stood at $10.7 billion (down 18.73% YoY), while the FY2025 annual figure was $13.2 billion, up 6.03% from the prior year.
- Receivables declined to $10.7 billion in Q2 2026 per CELG-RI's latest filing, from $10.8 billion in the prior quarter.
- Across five years, Receivables topped out at $13.2 billion in Q3 2025 and bottomed at $9.9 billion in Q1 2022.
- Historically, Receivables has averaged $11.7 billion across 5 years, with a median of $11.8 billion in 2024.
- Annual changes were most pronounced in 2023 — Receivables gained 24.2% — and 2026, when it fell 18.73%.
- Bristol Myers Squibb's Receivables stood at $10.4 billion in 2022, then climbed by 9.11% to $11.3 billion in 2023, then decreased by 1.81% to $11.1 billion in 2024, then gained by 4.26% to $11.6 billion in 2025, then retreated by 8.14% to $10.7 billion in 2026.
- Business Quant data shows CELG-RI's Receivables at $10.7 billion in Q2 2026, $10.8 billion in Q1 2026, and $11.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 10.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.66 Bn |
| Mar 31, 2026 | 10.79 Bn |
| Dec 31, 2025 | 11.61 Bn |
| Sep 30, 2025 | 13.22 Bn |
| Jun 30, 2025 | 13.12 Bn |
| Mar 31, 2025 | 12.54 Bn |
| Dec 31, 2024 | 11.13 Bn |
| Sep 30, 2024 | 12.74 Bn |
| Jun 30, 2024 | 13.10 Bn |
| Mar 31, 2024 | 12.07 Bn |
| Dec 31, 2023 | 12.96 Bn |
| Sep 30, 2023 | 12.20 Bn |
| Jun 30, 2023 | 12.10 Bn |
| Mar 31, 2023 | 12.25 Bn |
| Dec 31, 2022 | 10.39 Bn |
| Sep 30, 2022 | 11.21 Bn |
| Jun 30, 2022 | 10.52 Bn |
| Mar 31, 2022 | 9.87 Bn |
| Dec 31, 2021 | 10.76 Bn |
| Sep 30, 2021 | 10.61 Bn |